RARE · Ultragenyx Pharmaceutical Inc. Common Stock
View on chartInsiders & Stakes
| Emil D. Kakkis President & CEO | ▲ Buy | Grant | 735,739 Shares held | 4/16/2026 | View profile |
| Kassberg Thomas Richard CBO & EVP | ▼ Sell | Tax Withholding | 264,730 Shares held | 3/3/2025 | View profile |
| Dennis Karl Huang EVP & Chief Tech Ops Officer | ▲ Buy | Grant | 147,845 Shares held | 4/16/2026 | View profile |
| John Richard Pinion See Remarks | ▲ Buy | Grant | 133,142 Shares held | 4/16/2026 | View profile |
| Erik Harris Director | ▲ Buy | Grant | 118,410 Shares held | 4/16/2026 | View profile |
| Eric Crombez EVP and Chief Medical Officer | ▼ Sell | Open Market | 111,189 Shares held | 5/5/2026 | View profile |
| Howard Horn CFO | ▼ Sell | Open Market | 96,295 Shares held | 8/3/2026 | View profile |
| Karah Herdman Parschauer EVP and General Counsel | ▼ Sell | Open Market | 92,562 Shares held | 8/3/2026 | View profile |
| Theodore Alan Huizenga SVP, Chief Accounting Officer | ▼ Sell | Open Market | 67,863 Shares held | 9/15/2026 | View profile |
| Mardi Dier CFO & Executive Vice President | ▼ Sell | Open Market | 66,695 Shares held | 10/14/2022 | View profile |
| Bedrosian Camille L Chief Medical Officer | ▼ Sell | Open Market | 46,720 Shares held | 3/1/2023 | View profile |
| Michael Narachi Director | ▲ Buy | Grant | 40,441 Shares held | 5/14/2026 | View profile |
| Daniel G. Welch Director | ▲ Buy | Grant | 40,441 Shares held | 5/14/2026 | View profile |
| Deborah Dunsire Director | ▲ Buy | Grant | 38,566 Shares held | 5/14/2026 | View profile |
| Matthew K. Fust Director | ▲ Buy | Grant | 33,696 Shares held | 5/14/2026 | View profile |
| Amrit Ray Director | ▲ Buy | Grant | 31,116 Shares held | 5/14/2026 | View profile |
| Shehnaaz Suliman President and COO | ▼ Sell | Open Market | 27,951 Shares held | 5/18/2026 | View profile |
| Corazon (Corsee) D. Sanders Director | ▼ Sell | Open Market | 21,095 Shares held | 6/15/2026 | View profile |
| Ekman Lars Director | ▲ Buy | Grant | 17,745 Shares held | 6/24/2022 | View profile |
Transaction History
| Theodore Alan Huizenga | ▼ Sell | Open Market | 1,283 | $17K | 9/15/2026 |
| Theodore Alan Huizenga | ▼ Sell | Open Market | 161 | $2K | 9/3/2026 |
| Karah Herdman Parschauer | ▼ Sell | Open Market | 1,900 | $47K | 8/3/2026 |
| Howard Horn | ▼ Sell | Open Market | 4,696 | $117K | 8/3/2026 |
| Howard Horn | ▼ Sell | Open Market | 4,698 | $156K | 7/1/2026 |
| Corazon (Corsee) D. Sanders | ▼ Sell | Open Market | 2,000 | $50K | 6/15/2026 |
| Karah Herdman Parschauer | ▼ Sell | Open Market | 1,899 | $47K | 6/15/2026 |
| Howard Horn | ▼ Sell | Open Market | 4,653 | $111K | 6/1/2026 |
| Shehnaaz Suliman | ▼ Sell | Open Market | 5,740 | $144K | 5/18/2026 |
| Matthew K. Fust | ▲ Buy | Grant | 7,751 | $0 | 5/14/2026 |
| Shehnaaz Suliman | ▲ Buy | Grant | 7,751 | $0 | 5/14/2026 |
| Amrit Ray | ▲ Buy | Grant | 7,751 | $0 | 5/14/2026 |
| Corazon (Corsee) D. Sanders | ▲ Buy | Grant | 7,751 | $0 | 5/14/2026 |
| Michael Narachi | ▲ Buy | Grant | 7,751 | $0 | 5/14/2026 |
| Daniel G. Welch | ▲ Buy | Grant | 7,751 | $0 | 5/14/2026 |
| Deborah Dunsire | ▲ Buy | Grant | 7,751 | $0 | 5/14/2026 |
| Eric Crombez | ▼ Sell | Open Market | 344 | $9K | 5/5/2026 |
| Howard Horn | ▼ Sell | Open Market | 4,683 | $117K | 5/1/2026 |
| Theodore Alan Huizenga | ▲ Buy | Grant | 20,241 | $0 | 4/22/2026 |
| Emil D. Kakkis | ▲ Buy | Grant | 76,745 | $0 | 4/16/2026 |
| Dennis Karl Huang | ▲ Buy | Grant | 23,116 | $0 | 4/16/2026 |
| John Richard Pinion | ▲ Buy | Grant | 23,116 | $0 | 4/16/2026 |
| Karah Herdman Parschauer | ▲ Buy | Grant | 28,895 | $0 | 4/16/2026 |
| Erik Harris | ▲ Buy | Grant | 28,895 | $0 | 4/16/2026 |
| Eric Crombez | ▲ Buy | Grant | 34,674 | $0 | 4/16/2026 |
| Howard Horn | ▲ Buy | Grant | 34,674 | $0 | 4/16/2026 |
| Howard Horn | ▼ Sell | Open Market | 4,683 | $98K | 4/1/2026 |
| Karah Herdman Parschauer | ▼ Sell | Open Market | 3,508 | $80K | 3/10/2026 |
| Karah Herdman Parschauer | ▼ Sell | Open Market | 6,018 | $129K | 3/6/2026 |
| Howard Horn | ▼ Sell | Open Market | 1,635 | $37K | 3/3/2026 |
| John Richard Pinion | ▼ Sell | Open Market | 10,029 | $229K | 3/2/2026 |
| Erik Harris | ▼ Sell | Open Market | 10,539 | $240K | 3/2/2026 |
| Emil D. Kakkis | ▼ Sell | Open Market | 54,404 | $1.2M | 3/2/2026 |
| Karah Herdman Parschauer | ▼ Sell | Open Market | 8,135 | $185K | 3/2/2026 |
| Theodore Alan Huizenga | ▼ Sell | Tax Withholding | 148 | $3K | 3/2/2026 |
| Theodore Alan Huizenga | ▼ Sell | Open Market | 1,632 | $37K | 3/2/2026 |
| Howard Horn | ▼ Sell | Open Market | 5,290 | $121K | 3/2/2026 |
| Howard Horn | ▼ Sell | Open Market | 3,119 | $70K | 3/2/2026 |
| Dennis Karl Huang | ▼ Sell | Tax Withholding | 999 | $23K | 3/2/2026 |
| Eric Crombez | ▼ Sell | Open Market | 7,029 | $160K | 3/2/2026 |
| John Richard Pinion | ▲ Buy | Grant | 11,137 | $0 | 3/1/2026 |
| Erik Harris | ▲ Buy | Grant | 11,643 | $0 | 3/1/2026 |
| Emil D. Kakkis | ▲ Buy | Grant | 71,177 | $0 | 3/1/2026 |
| Karah Herdman Parschauer | ▲ Buy | Grant | 11,137 | $0 | 3/1/2026 |
| Howard Horn | ▲ Buy | Grant | 6,143 | $0 | 3/1/2026 |
| Dennis Karl Huang | ▲ Buy | Grant | 11,137 | $0 | 3/1/2026 |
| Eric Crombez | ▲ Buy | Grant | 11,643 | $0 | 3/1/2026 |
| Howard Horn | ▼ Sell | Open Market | 3,061 | $72K | 2/2/2026 |
| Howard Horn | ▼ Sell | Open Market | 3,150 | $72K | 1/2/2026 |
| Theodore Alan Huizenga | ▼ Sell | Open Market | 85 | $3K | 12/29/2025 |
| Howard Horn | ▼ Sell | Open Market | 3,081 | $112K | 12/10/2025 |
| Howard Horn | ▼ Sell | Open Market | 7,942 | $250K | 10/13/2025 |
| Theodore Alan Huizenga | ▼ Sell | Open Market | 64 | $2K | 9/18/2025 |
| Karah Herdman Parschauer | ▼ Sell | Open Market | 2,450 | $76K | 9/12/2025 |
| Theodore Alan Huizenga | ▼ Sell | Open Market | 84 | $3K | 9/5/2025 |
| Corazon (Corsee) D. Sanders | ▼ Sell | Open Market | 2,405 | $90K | 6/20/2025 |
| Shehnaaz Suliman | ▲ Buy | Grant | 5,740 | $0 | 5/15/2025 |
| Daniel G. Welch | ▲ Buy | Grant | 5,740 | $0 | 5/15/2025 |
| Corazon (Corsee) D. Sanders | ▲ Buy | Grant | 5,740 | $0 | 5/15/2025 |
| Michael Narachi | ▲ Buy | Grant | 5,740 | $0 | 5/15/2025 |
| Matthew K. Fust | ▲ Buy | Grant | 5,740 | $0 | 5/15/2025 |
| Deborah Dunsire | ▲ Buy | Grant | 5,740 | $0 | 5/15/2025 |
| Amrit Ray | ▲ Buy | Grant | 5,740 | $0 | 5/15/2025 |
| Eric Crombez | ▼ Sell | Open Market | 520 | $20K | 5/5/2025 |
| Eric Crombez | ▼ Sell | Open Market | 242 | $8K | 4/21/2025 |
| Howard Horn | ▼ Sell | Open Market | 1,785 | $72K | 3/6/2025 |
| Erik Harris | ▼ Sell | Open Market | 15,103 | $636K | 3/3/2025 |
| Dennis Karl Huang | ▼ Sell | Tax Withholding | 1,348 | $58K | 3/3/2025 |
| Theodore Alan Huizenga | ▼ Sell | Open Market | 967 | $41K | 3/3/2025 |
| Theodore Alan Huizenga | ▼ Sell | Tax Withholding | 141 | $6K | 3/3/2025 |
| Kassberg Thomas Richard | ▼ Sell | Open Market | 6,028 | $254K | 3/3/2025 |
| Kassberg Thomas Richard | ▼ Sell | Tax Withholding | 508 | $22K | 3/3/2025 |
| Karah Herdman Parschauer | ▼ Sell | Open Market | 12,846 | $541K | 3/3/2025 |
| Eric Crombez | ▼ Sell | Open Market | 8,945 | $377K | 3/3/2025 |
| John Richard Pinion | ▼ Sell | Open Market | 14,439 | $608K | 3/3/2025 |
| John Richard Pinion | ▼ Sell | Tax Withholding | 31 | $1K | 3/3/2025 |
| Emil D. Kakkis | ▼ Sell | Open Market | 73,434 | $3.1M | 3/3/2025 |
| Erik Harris | ▲ Buy | Grant | 16,813 | $0 | 3/1/2025 |
| Erik Harris | ▲ Buy | Grant | 18,443 | $0 | 3/1/2025 |
| Dennis Karl Huang | ▲ Buy | Grant | 14,494 | $0 | 3/1/2025 |
| Dennis Karl Huang | ▲ Buy | Grant | 18,443 | $0 | 3/1/2025 |
| Theodore Alan Huizenga | ▲ Buy | Grant | 9,392 | $0 | 3/1/2025 |
| Howard Horn | ▲ Buy | Grant | 15,653 | $0 | 3/1/2025 |
| Karah Herdman Parschauer | ▲ Buy | Grant | 14,494 | $0 | 3/1/2025 |
| Kassberg Thomas Richard | ▲ Buy | Grant | 18,443 | $0 | 3/1/2025 |
| Karah Herdman Parschauer | ▲ Buy | Grant | 18,443 | $0 | 3/1/2025 |
| Eric Crombez | ▲ Buy | Grant | 16,813 | $0 | 3/1/2025 |
| Eric Crombez | ▲ Buy | Grant | 14,971 | $0 | 3/1/2025 |
| John Richard Pinion | ▲ Buy | Grant | 14,494 | $0 | 3/1/2025 |
| John Richard Pinion | ▲ Buy | Grant | 18,443 | $0 | 3/1/2025 |
| Emil D. Kakkis | ▲ Buy | Grant | 43,268 | $0 | 3/1/2025 |
| Emil D. Kakkis | ▲ Buy | Grant | 107,292 | $0 | 3/1/2025 |
| Emil D. Kakkis | ▼ Sell | Open Market | 25,000 | $1.1M | 2/28/2025 |
| Karah Herdman Parschauer | ▼ Sell | Open Market | 2,230 | $96K | 2/27/2025 |
| Karah Herdman Parschauer | ▼ Sell | Open Market | 760 | $32K | 2/27/2025 |
| Emil D. Kakkis | ▼ Sell | Open Market | 11,727 | $495K | 12/30/2024 |
| Theodore Alan Huizenga | ▼ Sell | Gift | 648 | $0 | 12/10/2024 |
| Emil D. Kakkis | ▼ Sell | Open Market | 8,273 | $414K | 12/10/2024 |
| Emil D. Kakkis | ▼ Sell | Gift | 20,000 | $0 | 12/9/2024 |
| Howard Horn | ▼ Sell | Open Market | 7,465 | $394K | 10/10/2024 |
| Theodore Alan Huizenga | ▲ Buy | Grant | 700 | $0 | 9/16/2024 |
| Emil D. Kakkis | ▼ Sell | Open Market | 20,000 | $1.1M | 9/3/2024 |
| Theodore Alan Huizenga | ▼ Sell | Open Market | 91 | $5K | 9/3/2024 |
| Emil D. Kakkis | ▼ Sell | Open Market | 20,000 | $1.0M | 8/6/2024 |
| Corazon (Corsee) D. Sanders | ▼ Sell | Open Market | 584 | $24K | 7/2/2024 |
| Amrit Ray | ▲ Buy | Grant | 5,345 | $0 | 6/18/2024 |
| Matthew K. Fust | ▲ Buy | Grant | 5,345 | $0 | 6/18/2024 |
| Daniel G. Welch | ▲ Buy | Grant | 5,345 | $0 | 6/18/2024 |
| Michael Narachi | ▲ Buy | Grant | 5,345 | $0 | 6/18/2024 |
| Corazon (Corsee) D. Sanders | ▲ Buy | Grant | 5,345 | $0 | 6/18/2024 |
| Shehnaaz Suliman | ▲ Buy | Grant | 5,345 | $0 | 6/18/2024 |
| Deborah Dunsire | ▲ Buy | Grant | 5,345 | $0 | 6/18/2024 |
| Karah Herdman Parschauer | ▼ Sell | Open Market | 9,806 | $441K | 6/12/2024 |
| Corazon (Corsee) D. Sanders | ▼ Sell | Open Market | 1,737 | $71K | 6/10/2024 |
| Eric Crombez | ▼ Sell | Open Market | 354 | $15K | 5/2/2024 |
| Eric Crombez | ▼ Sell | Open Market | 142 | $6K | 4/18/2024 |
| Theodore Alan Huizenga | ▼ Sell | Tax Withholding | 14 | $592 | 4/16/2024 |
| Kassberg Thomas Richard | ▼ Sell | Open Market | 11,509 | $575K | 3/11/2024 |
| Matthew K. Fust | ▼ Sell | Open Market | 2,145 | $109K | 3/7/2024 |
| Matthew K. Fust | ▼ Sell | Open Market | 2,550 | $130K | 3/7/2024 |
| Matthew K. Fust | ▼ Sell | Open Market | 7,500 | $382K | 3/7/2024 |
| John Richard Pinion | ▲ Buy | Grant | 957 | $0 | 3/1/2024 |
| John Richard Pinion | ▼ Sell | Tax Withholding | 60 | $3K | 3/1/2024 |
| John Richard Pinion | ▼ Sell | Open Market | 4,173 | $224K | 3/1/2024 |
| Theodore Alan Huizenga | ▲ Buy | Grant | 13,950 | $0 | 3/1/2024 |
| Erik Harris | ▼ Sell | Open Market | 4,768 | $256K | 3/1/2024 |
| Emil D. Kakkis | ▲ Buy | Grant | 38,428 | $0 | 3/1/2024 |
| Emil D. Kakkis | ▼ Sell | Tax Withholding | 17,417 | $935K | 3/1/2024 |
| Emil D. Kakkis | ▲ Buy | Grant | 3,132 | $0 | 3/1/2024 |
| Howard Horn | ▲ Buy | Grant | 19,400 | $0 | 3/1/2024 |
| Karah Herdman Parschauer | ▲ Buy | Grant | 17,800 | $0 | 3/1/2024 |
| Karah Herdman Parschauer | ▲ Buy | Grant | 957 | $0 | 3/1/2024 |
| Karah Herdman Parschauer | ▼ Sell | Open Market | 3,756 | $202K | 3/1/2024 |
| Kassberg Thomas Richard | ▲ Buy | Grant | 17,800 | $0 | 3/1/2024 |
| Kassberg Thomas Richard | ▲ Buy | Grant | 957 | $0 | 3/1/2024 |
| Kassberg Thomas Richard | ▼ Sell | Tax Withholding | 274 | $15K | 3/1/2024 |
| Kassberg Thomas Richard | ▼ Sell | Open Market | 1,011 | $54K | 3/1/2024 |
| Dennis Karl Huang | ▲ Buy | Grant | 17,800 | $0 | 3/1/2024 |
| Dennis Karl Huang | ▲ Buy | Grant | 957 | $0 | 3/1/2024 |
| Dennis Karl Huang | ▼ Sell | Tax Withholding | 470 | $25K | 3/1/2024 |
| John Richard Pinion | ▲ Buy | Grant | 17,800 | $0 | 3/1/2024 |
| Theodore Alan Huizenga | ▼ Sell | Tax Withholding | 121 | $6K | 3/1/2024 |
| Theodore Alan Huizenga | ▼ Sell | Open Market | 341 | $18K | 3/1/2024 |
| Eric Crombez | ▲ Buy | Grant | 19,400 | $0 | 3/1/2024 |
| Eric Crombez | ▼ Sell | Open Market | 1,238 | $67K | 3/1/2024 |
| Erik Harris | ▲ Buy | Grant | 19,400 | $0 | 3/1/2024 |
| Erik Harris | ▲ Buy | Grant | 957 | $0 | 3/1/2024 |
| Emil D. Kakkis | ▼ Sell | Open Market | 30,000 | $1.4M | 2/7/2024 |
| Theodore Alan Huizenga | ▲ Buy | Option Exercise | 3,000 | $63K | 1/2/2024 |
| Emil D. Kakkis | ▼ Sell | Open Market | 30,000 | $1.4M | 12/29/2023 |
| Theodore Alan Huizenga | ▲ Buy | Grant | 1,000 | $0 | 12/20/2023 |
| Kassberg Thomas Richard | ▲ Buy | Option Exercise | 39,878 | $274K | 10/23/2023 |
| Kassberg Thomas Richard | ▼ Sell | Open Market | 39,878 | $1.3M | 10/23/2023 |
| Emil D. Kakkis | ▲ Buy | Option Exercise | 47,853 | $328K | 10/19/2023 |
| Emil D. Kakkis | ▼ Sell | Open Market | 47,853 | $1.6M | 10/19/2023 |
| Howard Horn | ▲ Buy | Grant | 80,366 | $0 | 10/9/2023 |
| Theodore Alan Huizenga | ▲ Buy | Option Exercise | 2,000 | $42K | 9/7/2023 |
| Theodore Alan Huizenga | ▼ Sell | Open Market | 2,000 | $82K | 9/7/2023 |
| Theodore Alan Huizenga | ▼ Sell | Open Market | 163 | $6K | 9/7/2023 |
| Erik Harris | ▼ Sell | Open Market | 6,000 | $228K | 9/5/2023 |
| Theodore Alan Huizenga | ▼ Sell | Open Market | 883 | $33K | 9/1/2023 |
| Theodore Alan Huizenga | ▼ Sell | Open Market | 87 | $3K | 9/1/2023 |
| Corazon (Corsee) D. Sanders | ▼ Sell | Open Market | 585 | $27K | 6/30/2023 |
| Erik Harris | ▼ Sell | Open Market | 305 | $15K | 6/19/2023 |
| Corazon (Corsee) D. Sanders | ▼ Sell | Open Market | 1,485 | $77K | 6/8/2023 |
| Amrit Ray | ▲ Buy | Grant | 3,860 | $0 | 6/7/2023 |
| Matthew K. Fust | ▲ Buy | Grant | 3,860 | $0 | 6/7/2023 |
| Matthew K. Fust | ▼ Sell | Other | 3,300 | $171K | 6/7/2023 |
| Corazon (Corsee) D. Sanders | ▲ Buy | Grant | 3,860 | $0 | 6/7/2023 |
| Shehnaaz Suliman | ▲ Buy | Grant | 3,860 | $0 | 6/7/2023 |
| Michael Narachi | ▲ Buy | Grant | 3,860 | $0 | 6/7/2023 |
| Deborah Dunsire | ▲ Buy | Grant | 3,860 | $0 | 6/7/2023 |
| Daniel G. Welch | ▲ Buy | Grant | 3,860 | $0 | 6/7/2023 |
| John Richard Pinion | ▼ Sell | Open Market | 2,012 | $101K | 5/18/2023 |
| Theodore Alan Huizenga | ▲ Buy | Option Exercise | 3,000 | $63K | 5/9/2023 |
| Karah Herdman Parschauer | ▼ Sell | Open Market | 4,378 | $197K | 5/4/2023 |
| Eric Crombez | ▲ Buy | Grant | 4,658 | $0 | 5/1/2023 |
| Theodore Alan Huizenga | ▼ Sell | Tax Withholding | 14 | $535 | 4/16/2023 |
| Theodore Alan Huizenga | ▼ Sell | Other | 181 | $7K | 4/16/2023 |
| Bedrosian Camille L | ▲ Buy | Grant | 2,663 | $0 | 3/1/2023 |
| Bedrosian Camille L | ▼ Sell | Open Market | 3,881 | $176K | 3/1/2023 |
| Karah Herdman Parschauer | ▲ Buy | Grant | 2,663 | $0 | 3/1/2023 |
| Karah Herdman Parschauer | ▲ Buy | Grant | 22,000 | $0 | 3/1/2023 |
| Karah Herdman Parschauer | ▼ Sell | Open Market | 3,161 | $143K | 3/1/2023 |
| Kassberg Thomas Richard | ▲ Buy | Grant | 2,663 | $0 | 3/1/2023 |
| Kassberg Thomas Richard | ▲ Buy | Grant | 22,000 | $0 | 3/1/2023 |
| Emil D. Kakkis | ▲ Buy | Grant | 46,200 | $0 | 3/1/2023 |
| Emil D. Kakkis | ▼ Sell | Tax Withholding | 16,140 | $737K | 3/1/2023 |
| Erik Harris | ▲ Buy | Grant | 2,663 | $0 | 3/1/2023 |
| Erik Harris | ▲ Buy | Grant | 22,000 | $0 | 3/1/2023 |
| Erik Harris | ▼ Sell | Open Market | 3,664 | $166K | 3/1/2023 |
| Kassberg Thomas Richard | ▼ Sell | Open Market | 1,968 | $89K | 3/1/2023 |
| Kassberg Thomas Richard | ▼ Sell | Other | 3,394 | $155K | 3/1/2023 |
| Theodore Alan Huizenga | ▲ Buy | Grant | 7,590 | $0 | 3/1/2023 |
| Theodore Alan Huizenga | ▼ Sell | Open Market | 100 | $5K | 3/1/2023 |
| Theodore Alan Huizenga | ▼ Sell | Other | 1,333 | $61K | 3/1/2023 |
| Dennis Karl Huang | ▲ Buy | Grant | 2,663 | $0 | 3/1/2023 |
| Dennis Karl Huang | ▲ Buy | Grant | 22,000 | $0 | 3/1/2023 |
| Dennis Karl Huang | ▼ Sell | Open Market | 389 | $18K | 3/1/2023 |
| Dennis Karl Huang | ▼ Sell | Other | 10,599 | $484K | 3/1/2023 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
RARE FDA approves Fayuvi, triggers $203M voucher sale
Ultragenyx Pharmaceutical received FDA approval for its gene therapy Fayuvi. The approval was followed by a second sale of a priority review voucher, bringing in about $203 million within a week. The cash from the voucher sale adds to the company’s resources as it looks to expand its approved product portfolio. Analysts are evaluating whether the newly approved product can support the next growth phase.
RARE FDA approves Fayuvi, triggers $203M voucher sale. Ultragenyx Pharmaceutical received FDA approval for its gene therapy Fayuvi. The approval was followed by a second sale of a priority review voucher, bringing in about $203 million within a week. The cash from the voucher sale adds to the company’s resources as it looks to expand its approved product portfolio. Analysts are evaluating whether the newly approved product can support the next growth phase.